Citations

Clear

3042 citation(s) found for "Kumar, S".

Intraoperative Radiation Therapy (IORT) in Gynecologic Cancers: A Scoping Review
Erdemoğlu, Evrim , Ostby, Stuart A. , Senthilkumar, Sanjanaa , Kumar, Amanika , Vora, Sujay A., James, Sarah E. , Butler, Kristina , Butler, Kristina A., Kumar, Amanika , Chen, Longwen

Mayo Clinic

Cancers | April 20, 2025 | Volume: 17 | Issue: 8 | Pages: 1356

10.3390/cancers17081356 | PMID 40282536 Get It

Objective: We aimed to analyze the current literature for IORT in gynecological cancers and summarized clinical outcomes regarding patient selection. Methods: A systematic search was conducted utilizing PUBMED, Embase, and CINAHL to identify studies following PRISMA-ScR guidelines. A PICOS structure was utilized: population: patients with epithelial gynecological cancers; intervention: IORT; C: a comparator was not required, as we aimed to analyze patient selection; outcome: clinical outcomes and overall survival; and S: experimental and quasi-experimental analytical observational studies and descriptive observational studies, excluding case series published in English and limited to the last 10 years. Data extraction was conducted for patient selection, IORT, oncological outcomes, and morbidity. Results: A total of 707 results were identified, and 509 studies were uploaded to Covidence for screening after removing duplications. Of the 21 eligible studies, 9 were included in the final review. The total number of patients included was 348. The studies were retrospective single-institution studies, except for one. There was significant heterogeneity in their design and protocols. IORT was exclusively used for recurrent and advanced stage gynecological cancers adjunct to pelvic exenteration or laterally extended endopelvic resections with variable indications across institutions. The mean number of IORT patients per study was 2.8 per year. Survival rates were variable and dependent on the surgical margin. Endometrial cancer had a favorable outcome compared to vulvar and cervical cancers. Conclusions: Current clinical practice, as demonstrated by the research, is consistent with NCCN guidelines that endorse the application of IORT in instances of recurrent cervical, vaginal, and vulvar malignancies; however, there are no established recommendations for primary tumors. The analysis shows that there are gaps in our knowledge, mainly regarding the status of the margins, the criteria used to choose patients, and the outcomes that are specific to each histology. The standardization of protocols and prospectively powered studies are needed to refine patient selection criteria.
Pentoxifylline use in alcohol-associated hepatitis with acute kidney injury does not improve survival: a global study
Idalsoaga, Francisco , Caldentey, Vicente, Arnold, Jorge , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Khan, Mohammad Qasim, Mortuza, Rokhsana , Malhi, Gurpreet, Islam, Alvi H. , Ramírez, Carolina , Echavarria, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Tijera, María Fátima Higuera-De La, Al‐Karaghouli, Mustafa , Havaj, Daniel Ján , Shah, Vijay H. , Kamath, Patrick S. , SIMONETTO, DOUGLAS, Havaj, Daniel J , Shah, Vijay, Arab, Juan P , Poca, Maria , Ventura Cots, Meritxell , Elfeki, Mohamed A , Cuyas, Berta , Díaz, Luis Antonio , Dunn, Winston , Mehta, Heer, Ayares, Gustavo , Sarin, Shiv Kumar , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Khan, Mohammad Qasim, Guizzetti, Leonardo , Cabezas, Joaquín , Echavarria, Victor, Soriano, German , Abraldeṣ, Juan G. , Skladaný, Lubomir , Rincón, Diego , Arrese, Marco , Bataller, Ramon A , Arab, Juan Pablo

Mayo Clinic

eGastroenterology | April 20, 2025 | Volume: 3 | Issue: 2 | Pages: e100179

10.1136/egastro-2024-100179 | PMID 40276593 Get It

Background Severe alcohol-associated hepatitis (sAH) is a life-threatening condition with high mortality, where corticosteroid use is the only treatment that has shown short-term benefits. Pentoxifylline, an anti-tumour necrosis factor-alpha agent, has been proposed for its potential to improve outcomes, especially in patients with acute kidney injury (AKI). We aimed to evaluate the impact of pentoxifylline on mortality in patients with sAH and AKI in a well-characterised global cohort. Methods We conducted a retrospective, registry-based study including patients meeting the National Institute on Alcohol Abuse and Alcoholism clinical criteria for sAH and AKI. Mortality was the primary endpoint, with liver transplantation as a competing risk. Statistical analysis included Cox regression and Kaplan-Meier survival estimates. Results We included 525 patients from 20 centres across eight countries. The median age was 48 years, with 26.1% females, and 76.9% had a history of cirrhosis. Multivariable Cox regression models showed that pentoxifylline use was not associated with survival (HR 1.20, 95% CI 0.85 to 1.69, p=0.291). Factors associated with mortality included age (HR 1.23, 95% CI 1.10 to 1.36, p<0.001), Model for End-Stage Liver Disease score at admission (HR 1.06, 95% CI 1.04 to 1.08, p<0.001) and renal replacement therapy use (HR 1.39, 95% CI 1.05 to 1.84, p=0.019). The main causes of death were multiple organ failure (42%), infections (10%), oesophageal varices bleeding (7%) and renal failure (6%). Conclusion Pentoxifylline showed no significant benefit on mortality in patients with sAH and AKI. Further studies are needed to refine treatment strategies for this high-risk group.
Challenges in Automating Extraction of Real-World Radiographic Images and Adverse Events: Lessons From the ICAREdata Initiative
Piantadosi, Steven , Campbell, Nancy , Chow, Selina , Elrahi, Cassandra , Knopp, Michael V. , Kumar, Vaibhav , Lerro, Catherine C. , Rivera, Donna R. , Quina, Andre , Casagni, Michelle , Mohammed-Rajput, Nareesa, Casagni, Michelle , Mohammed-Rajput, Nareesa , Tevaarwerk, Amye J , George, Suzanne , Chow, Selina , Kluetz, Paul Gustav , Tevaarwerk, Amyé , George, Suzanne

Mayo Clinic

JCO Clinical Cancer Informatics | April 18, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/cci-24-00319 | PMID 40249879 Get It

Truly COSMIC: An ASH Research Collaborative First
Kumar, Shaji, Usmani, Saad Z. , Kumar, Shaji

Mayo Clinic

The Hematologist | April 17, 2025 | Volume: 22 | Issue: 3 | Pages: No page available

10.1182/hem.v22.3.202539 Get It

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
Puttkammer, Jenna R. , Barreto, Jason N. , Jensen, Chelsee , Nedved, Adrienne, Wilson-Miller, Justine L., Cole, Kristin C., Holmes, Lucy , Kosobud, A., Kapoor, Prashant , Gertz, Morie A. , Dingli, David , Kumar, Shaji , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Binder, Moritz , Sandahl, Tyler B. , Mara, Kristin C. , Jensen, Chelsee J , Nedved, Adrienne N , Holmes, Lucy M, Kosobud, Allison R, Gonsalves, Wilson , Kumar, Shaji K , Kourelis, Taxiarchis V, Warsame, Rahma , Binder, Moritz , Cook, Joselle M , Lin, Yi , Sandahl, Tyler B , Gertz, Morie A , Dingli, David , Mara, Kristin C , Holmes, Lucy M., Kosobud, Allison R., Gonsalves, Wilson I. , Cook, Joselle , Lin, Yi

Mayo Clinic

JCO Oncology Practice | April 15, 2025 | Volume: 22 | Issue: 1 | Pages: 83-90

10.1200/op-24-00930 | PMID 40233295 Get It

PURPOSE Cytokine release syndrome (CRS) of any grade occurs in 56%-80% of bispecific antibodies (BsAbs) used in multiple myeloma (MM). Risk mitigation strategies are required to expedite escalation of care if toxicities develop. The rarity of grade 3 or 4 CRS compels protocolized outpatient management of BsAbs as outpatient practice may avoid hospital admissions and costly resource utilization without compromising safety. MATERIALS AND METHODS Patients with MM who received BsAb step-up dosing (SUD) from August 23, 2023, to March 29, 2024, were enrolled. Baseline demographics, patient outcomes, and CRS management were reviewed to assess the safety of outpatient practice. Resource utilization was also analyzed. RESULTS In this study, 34 patients received outpatient SUD of BsAbs (teclistamab n = 17, talequetamab n = 17) with 16 remaining outpatient throughout the entire SUD period. CRS occurred in seven patients who did not require hospitalization, demonstrating the safety of outpatient management of BsAb toxicity, regardless of low-grade CRS. CRS was observed in 24 patients (maximum grade 2) and immune effector cell–associated neurotoxicity syndrome in four patients (maximum grade 3). All patients with CRS received steroids, including 12 patients at home when instructed. Tocilizumab was given to 13 patients, accounting for 18 doses. If all doses of BsAbs and tocilizumab were given outpatient, the medication margin would be $115,004 in US dollars (USD). CONCLUSION An outpatient-based practice for BsAb administration demonstrated safety and cost savings. The description of our practice and results of this study provide valuable insights into the safety, feasibility, and resource stewardship of outpatient management of BsAbs. Future research should attempt to predict and stratify CRS risk to deliver a tailored supportive strategy and continued increase of outpatient management.
A 5-HT-mediated urethral defense against urinary tract infections
Ambrogi, Marcela , Hernandez, Laura L. , Strand, Douglas W. , Romero, Michael F. , Barasch, Jonathan , Ridlon, Monica , Vezina, Chad M. , Romero, Michael F , Barasch, Jonathan , Ridlon, Monica , Keil Stietz, Kimberly P , Vezina, Chad M , Strand, Douglas , Kumar, Sathish

Mayo Clinic

Proceedings of the National Academy of Sciences | April 14, 2025 | Volume: 122 | Issue: 16 | Pages: No page available

10.1073/pnas.2409754122 | PMID 40228121 Get It

The urethra is considered a passive conduit for urine. Here, we reveal a surprising multicellular signaling pathway guiding the urethra’s dynamic response to an invading pathogen. Using a genetic approach in female mice, we deposited uropathogenic Escherichia coli into the distal urethra to establish a model of ascending urinary tract infection that progresses to the bladder within 4 h. We show that urethral neuroendocrine cells (UNECs), and the serotonin they synthesize, protect the bladder from bacterial colonization. We tested the hypothesis that serotonin initiates urethral contraction to expel ascending bacteria. We identified transient receptor potential cation channel subfamily A member 1, a noncanonical lipopolysaccharide receptor, in human and mouse UNECs and localized the serotonin receptors (HTR) 2B and 3, as well as the calcium-activated chloride channel anoctamin 1 (ANO1) to the pacemaker cells of the human and mouse urethra, the interstitial cells of Cajal (ICCs). HTR2B or ANO1 activation is sufficient for urethral contraction and is required for serotonin-induced mouse urethral contraction. Our results support the hypothesis that the urethra actively surveils its environment and responds to an ascending pathogen by evoking UNECs and ICC to induce urethral contraction and pathogen expulsion.
Retrospective Pilot Study: Squamous Cell Carcinoma in Situ of the Head and Neck Treated With Topical 5-Fluorouracil
Kumar, Anagha , Asamoah, Eucabeth, Baum, Christian L.

Mayo Clinic

Dermatologic Surgery | April 10, 2025 | Volume: 51 | Issue: 9 | Pages: 898-900

10.1097/dss.0000000000004643 | PMID 40207780 Get It

Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Grogan, Martha , López-Jiménez, Francisco , Guthrie, Spencer , Kumar, Nisith, Langevin, R.Eugene, Lousada, Isabelle , Witteles, Ronald , Royyuru, Ajay K. , Rosenzweig, Michael , Cairns‐Smith, Sarah , Royyuru, Ajay , Ouyang, David , Lopez-Jimenez, Francisco , Kumar, Nisith, Langevin, Reuben

Mayo Clinic

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.036533 | PMID 40207501 Get It

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative review of published literature describes the performance of AI tools that use data from ECGs and echocardiography to improve identification of CA and challenges that hinder adoption of these tools. Thirteen studies met inclusion criteria with sample sizes ranging from 50 to 2451 patients. Four studies used ECG data, 8 used echocardiography data, and 1 used both. The CA gold standard was typically defined as a CA diagnosis in an institutional or other database but the requirements for these diagnoses were heterogenous across studies, and many did not distinguish among CA subtypes. AI model development varied considerably, and only 4 studies included external validation. The ability of models to predict CA ranged from 0.71 to 1.00, sensitivity ranged from 16% to 100%, and specificity from 75% to 100%. Only 1 study reported model performance across strata of sex, age, race, and CA type. Persistent challenges to AI adoption include usability, cost, value added, electronic health record/information technology interoperability, patient‐related factors, regulation, and privacy and liability. Published studies on AI for improved identification of CA show favorable performance measures but numerous methodologic and other challenges must be addressed before these tools are more widely adopted.
Efficient Separation of Related Substances in Clidinium Bromide and Chlordiazepoxide Hydrochloride Capsules using Reversed-phase Ultra-performance Liquid Chromatography
Kumar, Garimi Tirumala Jyothesh, Andrews, B. S. A. , Reddy, P. Sunil, Venugopal, Nutulapati V.S. , Vijayalakshmi, Kancharla , Abbaraju, V D N Kumar

Mayo Clinic

Research Journal of Pharmacy and Technology | April 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 372-378

10.52711/0974-360x.2025.00058 Get It

A validated reverse-phase ultra-performance liquid chromatography (UPLC) method has been developed for the precise determination of impurities in Clidinium Bromide (CDB) and Chlordiazepoxide Hydrochloride (CDH) Capsules. This study focuses on the separation of impurities, namely Benzylic acid (BZY) related to Clidinium, Chlordiazepoxide Related Compound A (CDRC-A), and Chlordiazepoxide Related Compound C (CDRC-C). The Water’s H-Class UPLC system, equipped with a PDA Detector, was employed with a 15µL loop size, operating at a detection wavelength of 215 nm in gradient mode with a flow rate of 0.3 mL/min, resulting in a total run time of 55 min. The chromatographic separation utilized a Waters Acquity UPLC BEH C18 column (150 mm × 2.1 mm i.d., 1.7 µm particle size) at a column temperature of 55°C. The method demonstrated robustness and accuracy with retention times for CDB (4.4), BZY (5.2), CDRC-A (8.5), CDH (12.1), and CDRC-C (33.8). The % Accuracy at 100% for CDB is 98.2, BZY is 0.0765, CDRC-A is 0.1350, CDH is 98.2 and CDRC-C is 101.0 respectively. LOQ values for CDB is 0.0756, BZY is 0.0765, CDRC-A is 0.1464, CDH is 0.0749 and CDRC-C is 0.1932. Linear responses were observed for all impurities, including CDB and CDH. This validated UPLC method is deemed more appropriate to regular QC analysis as well as Stability study analysis of CDB and CDH Capsules formulations.
Amyloid precursor protein and presenilin‐1 knock‐in immunodeficient mice exhibit intraneuronal Aβ pathology, microgliosis, and extensive neuronal loss
Yeapuri, Pravin, Foster, Emma G. , Kadry, Rana, Bhattarai, Shaurav , Lu, Yaman, Sil, Susmita , Sapkota, Roshan , Srivastava, Shefali , Kumar, Mohit , Mosley, R. Lee , Machhi, Jatin , Ikezu, Tsuneya , Poluektova, Larisa Y. , Gendelman, Howard Eliot

Mayo Clinic

Alzheimer's & Dementia | April 8, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70084 | PMID 40195277 Get It

AbstractINTRODUCTIONTransgenic mice overexpressing familial Alzheimer's disease (AD) mutations (FAD) show non‐physiological traits, and their immunocompetent backgrounds limit their use in AD immunotherapy research. Preclinical models that reflect human immune responses in AD are needed.METHODSUsing CRISPR‐Cas9, we developed single (NA) and double (NAPS) knock‐in (KI) amyloid precursor protein (APP)KM670,671NL (Swedish) and presenilin 1 (PS 1)M146VFAD mutations on an immunodeficient NOG (NOD.Cg‐PrkdcscidIl2rgtm1Sug/JicTac) background. The models were confirmed by Sanger sequencing and evaluated for AD‐like pathology.RESULTSBoth NA and NAPS mice developed pathology without overexpression artifacts. Mutation‐induced upregulation of APP‐CTF‐β led to intraneuronal human amyloid beta (Aβ) (6E10) deposits and amyloid‐associated microgliosis as early as 3 months, which increased with age. The addition of the PS 1M146V mutation doubled the amyloid load. The models displayed broad neuronal loss, resulting in brain atrophy in older mice.DISCUSSIONThese models replicate intraneuronal amyloid pathology and, with human immune reconstitution potential, enable novel studies of human immune responses in AD.Highlights A novel Alzheimer's disease (AD) knock‐in (KI) mouse was developed and characterized on an immunodeficient NOG background. The model provides a platform for human immune studies and the evaluation of immunotherapies for AD. The KI mice demonstrate intraneuronal Aβ deposits and amyloid‐associated microglial reactions. KI mice demonstrate extensive neuronal loss. Human immune reconstitution enables studies of infectious AD co‐morbidities, such as the human immunodeficiency and herpes simplex viruses.